These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 9789461)

  • 1. [Why is the DNA-strand-breaker, PCNDAC, effective to solid tumors?].
    Matsuda A; Sasaki T
    Tanpakushitsu Kakusan Koso; 1998 Oct; 43(13):1981-9. PubMed ID: 9789461
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of Down's syndrome critical locus gene SIM2-s as a drug therapy target for solid tumors.
    DeYoung MP; Tress M; Narayanan R
    Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4760-5. PubMed ID: 12676991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
    Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
    Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Design of a new antitumor nucleoside CNDAC, against solid tumors].
    Matsuda A
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):202-10. PubMed ID: 8611048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines.
    Crowe DL; Sinha UK
    Head Neck; 2006 Jan; 28(1):15-23. PubMed ID: 16302195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
    Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
    Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer.
    Oakley R; Phillips E; Hooper R; Wilson D; Partridge M
    Clin Cancer Res; 2002 Jun; 8(6):1984-94. PubMed ID: 12060644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer.
    Zou Y; Zong G; Ling YH; Perez-Soler R
    Cancer Gene Ther; 2000 May; 7(5):683-96. PubMed ID: 10830716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation?
    Magnusson KP; Satalino R; Qian W; Klein G; Wiman KG
    Oncogene; 1998 Nov; 17(18):2333-7. PubMed ID: 9811464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
    Wiman KG
    Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease.
    Lechel A; Holstege H; Begus Y; Schienke A; Kamino K; Lehmann U; Kubicka S; Schirmacher P; Jonkers J; Rudolph KL
    Gastroenterology; 2007 Apr; 132(4):1465-75. PubMed ID: 17433324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH.
    Forslund A; Kressner U; Lönnroth C; Andersson M; Lindmark G; Lundholm K
    Int J Oncol; 2002 Aug; 21(2):409-15. PubMed ID: 12118339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
    Olive KP; Tuveson DA; Ruhe ZC; Yin B; Willis NA; Bronson RT; Crowley D; Jacks T
    Cell; 2004 Dec; 119(6):847-60. PubMed ID: 15607980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus-p53-mediated gene therapy of anaplastic large cell lymphoma with t(2;5) in a nude mouse model.
    Turturro F; Heineke HL; Drevyanko TF; Link CJ; Seth P
    Gene Ther; 2000 Jun; 7(11):930-3. PubMed ID: 10849552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent mutations of the Trp53, Hras1 and beta-catenin (Catnb) genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1 mice.
    Zhuang SM; Wiseman RW; Söderkvist P
    Oncogene; 2002 Aug; 21(36):5643-8. PubMed ID: 12165863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
    Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
    Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment.
    Chawengchao B; Petmitr S; Ponglikitmongkol M; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W
    Anticancer Res; 2001; 21(4A):2739-43. PubMed ID: 11724349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumors and evolution].
    Kozlov AP
    Vopr Onkol; 2008; 54(6):695-705. PubMed ID: 19241842
    [No Abstract]   [Full Text] [Related]  

  • 19. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
    Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
    Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis.
    Chang KW; Sarraj S; Lin SC; Tsai PI; Solt D
    Carcinogenesis; 2000 Jul; 21(7):1441-51. PubMed ID: 10874024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.